Shiraj Sen, M.D., Ph.D.

Provider Type: Physician

Specialties:

Hematology
Medical Oncology

Board Certifications:

Internal Medicine
Medical Oncology

Texas Oncology-Las Colinas Next Oncology
6750 N. MacArthur Blvd., Suite 250
Irving, TX 75039
T: 972-893-8800

Metro Area: Dallas, San Antonio

Spoken Language: English

Downloads

Biography

Education

Fellowship in Medical Oncology and Hematology
The University of Texas MD Anderson Cancer Center, Houston, TX
Residency in Internal Medicine
The University of Texas Southwestern Medical Center, Dallas, TX
Medical Doctorate
The University of Texas Medical School at Houston, Houston, TX
Doctor of Philosophy in Biomedical Sciences
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Accolades & Memberships

American Association of Cancer Research-Bristol Myers Squibb Merit Award (2017)
American Society of Clinical Oncology Conquer Cancer Foundation Merit Award (2016, 2018)
MD Anderson Cancer Center-Lyndon B. Johnson Hospital Clinical Fellow of the Year Award (2017)
MD Anderson Cancer Center Marion D. Edwards Award in Hepatic Oncology (2018)
MD Anderson Cancer Center Waun Ki Hong Award for Achievement in Clinical Investigation (2018)
Texas Society of Clinical Oncology Merit Award (2015 – 2017)

Publications

Histology-Agnostic Drug Development – Considering Issues Beyond the Tissue
Nature Reviews Clinical Oncology 2020, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
JCO Precision Oncology 2018, 2018

Latest News

Research Interest

Dr. Sen's research interest is in developing new, promising drugs to treat cancer through phase I clinical trials. Dr. Sen leads the phase I clinical trial group at NEXT Oncology Dallas and is committed to providing his patients access to the newest cancer treatment options available through phase I clinical trials when standard treatments are no longer effective for them.

Medical Practice

Genentech, Medical Oncologist, Medical Director, Product Development Oncology, (October 2020)
Sarah Cannon Research Institute at HealthONE, Medical Oncologist, Associate Director, Denver Drug Development Unit, Denver, CO (August 2018 – September 2020)